Retatrutide ZPHC — 40 mg (5 vials × 8 mg)

Description

RETATRUTIDE 40 MG KIT from ZPHC PHARMA is an advanced research-grade peptide targeting three metabolic hormone receptors:

• GLP-1 (Glucagon-like peptide-1)
• GIP (Gastric inhibitory polypeptide)
• Glucagon receptor

This triple agonist approach is designed to enhance weight loss, optimize glucose control, and boost metabolic performance. The compound is formulated strictly for research and investigational use in studies related to obesity, type 2 diabetes, and energy balance.

 Product Features

• Concentration: 8 MG of Retatrutide per vial
• Total Content: 40 MG per kit (5 vials)
• Form: Lyophilized powder (requires reconstitution)
• Storage Conditions: Refrigerate between 2°C – 8°C after reconstitution
• Purity: High-purity research-grade peptide

Key Research Benefits

• Supports Weight Reduction
  Acts centrally and peripherally to suppress appetite and improve fat oxidation
• Improves Insulin Sensitivity
  Promotes enhanced glucose uptake and insulin efficiency
• Triple-Receptor Mechanism
  A synergistic effect via GLP-1, GIP, and glucagon receptors
• Balances Energy Metabolism
  May improve energy expenditure and regulate lipid/glucose pathways

Suggested Research Protocol (For Investigational Use Only)

Reconstitute each vial with bacteriostatic water prior to administration.

Typical administration route in research settings: subcutaneous injection.

Dosage and frequency should be defined based on study goals, model, and duration.

Observed Side Effects (In Research Contexts)

• Mild to moderate nausea
• Gastrointestinal discomfort
• Decreased appetite
• Injection site reactions

All effects are dose-dependent and typically transient. Monitoring during long-term protocols is recommended.

 Research Use Contraindications

Not advised in test subjects with:

• History of thyroid C-cell tumors
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Allergy to peptide-based therapeutics or excipients